Recent studies demonstrate the potential of RMP1-14, a newly created anti-mouse PD-1 reagent , for boosting click here tumor immunotherapy . Unlike conventional approaches, R… Read More

Etaracizumab, formerly known as MEDI523 and later LM609, represents a novel method in anti-inflammatory therapy. This humanized protein is built to selectively neutralize the activity of complement factor , a essential component of the pathway involved in tissue damage. Studies have focused on i… Read More